A carregar...
Effect of Elagolix Exposure on Clinical Efficacy End Points in Phase III Trials in Women With Endometriosis‐Associated Pain: An Application of Markov Model
Elagolix is an oral gonadotropin‐releasing hormone antagonist approved by the US Food and Drug Administration (FDA) for the management of moderate‐to‐severe pain associated with endometriosis and in combination with estradiol/norethindrone acetate approved for the management of heavy menstrual bleed...
Na minha lista:
| Publicado no: | CPT Pharmacometrics Syst Pharmacol |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7438813/ https://ncbi.nlm.nih.gov/pubmed/32621325 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/psp4.12545 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|